Edition:
India

Theravance Biopharma and Mylan Expand YUPELRI Development and Commercialization Agreement to Include China and Adjacent Territories


Friday, 14 Jun 2019 

June 14 (Reuters) - Mylan NV ::THERAVANCE BIOPHARMA AND MYLAN EXPAND YUPELRI® (REVEFENACIN) DEVELOPMENT AND COMMERCIALIZATION AGREEMENT TO INCLUDE CHINA AND ADJACENT TERRITORIES.MYLAN NV - EXPANSION OF DEVELOPMENT & COMMERCIALIZATION DEAL FOR NEBULIZED REVEFENACIN TO INCLUDE CHINA & SOME ADJACENT TERRITORIES.MYLAN NV - THERAVANCE BIOPHARMA WILL RECEIVE AN UPFRONT PAYMENT OF $18.5 MILLION UNDER TERMS.MYLAN NV - MYLAN WILL BE RESPONSIBLE FOR ALL ASPECTS OF DEVELOPMENT AND COMMERCIALIZATION IN PARTNERED REGIONS.MYLAN NV - THERAVANCE BIOPHARMA ALSO TO BE ELIGIBLE TO RECEIVE ADDITIONAL POTENTIAL DEVELOPMENT AND SALES MILESTONES TOTALING $54 MILLION.